Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Structural and functional analysis of APOA5 mutations identifi ed in patients with severe hypertriglyceridemia

  • Mendoza-Barberá, Elena|||0000-0002-6374-4125
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Nilsson, Stefan K.
  • Lookene, Aivar
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Roig, Rosa|||0000-0002-3055-9791
  • Lechuga-Sancho, Alfonso M.
  • Sloan, John H.
  • Fuentes-Prior, Pablo|||0000-0002-6618-3204
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
During the diagnosis of three unrelated patients with severe hypertriglyceridemia, three APOA5 mutations [p.(Ser232-Leu235)del, p.Leu253Pro, and p.Asp332ValfsX4] were found without evidence of concomitant LPL, APOC2, or GPIHBP1 mutations. The molecular mechanisms by which APOA5 mutations result in severe hypertriglyceridemia remain poorly understood, and the functional impairment/s induced by these specifi c mutations was not obvious. Therefore, we performed a thorough structural and functional analysis that included follow-up of patients and their closest relatives, measurement of apoA-V serum concentrations, and sequencing of the APOA5 gene in 200 nonhyperlipidemic controls. Further, we cloned, overexpressed, and purifi ed both wild-type and mutant apoA-V variants and characterized their capacity to activate LPL. The interactions of recombinant wild-type and mutated apoA-V variants with liposomes of different composition, heparin, LRP1, sortilin, and SorLA/LR11 were also analyzed. Finally, to explore the possible structural consequences of these mutations, we developed a three-dimensional model of full-length, lipid-free human apoA-V. A complex, wide array of impairments was found in each of the three mutants, suggesting that the specifi c residues affected are critical structural determinants for apoA-V function in lipoprotein metabolism and, therefore, that these APOA5 mutations are a direct cause of hypertriglyceridemia.Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc..
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer

  • Cedó, Lídia|||0000-0003-4354-3411
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Baila-Rueda, Lucía
  • Santos, David|||0000-0003-1157-4969
  • Grijalva, Victor
  • Martínez Cignoni, Melanie Raquel|||0000-0002-3469-7980
  • Carbó, José María|||0000-0001-8301-5360
  • Metso, Jari
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Valledor, Annabel F.|||0000-0003-4232-2633
  • Cenarro, Ana
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Fogelman, Alan M.
  • Reddy, Srinivasa T.
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. We aimed to determine the effects of human apoA-I overexpression and administration of specific apoA-I mimetic peptide (D-4F) on tumour progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a model of inherited breast cancer. Expression of human apoA-I in the mice did not affect tumour onset and growth in PyMT transgenic mice, despite an increase in the HDLc level. In contrast, D-4F treatment significantly increased tumour latency and inhibited the development of tumours. The effects of D-4F on tumour development were independent of 27-hydroxycholesterol. However, D-4F treatment reduced the plasma oxidized low-density lipoprotein (oxLDL) levels in mice and prevented oxLDL-mediated proliferative response in human breast adenocarcinoma MCF-7 cells. In conclusion, our study shows that D-4F, but not apoA-I-containing HDL, hinders tumour growth in mice with inherited breast cancer in association with a higher protection against LDL oxidative modification.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human ApoA-I overexpression enhances macrophage-specific reverse cholesterol transport but fails to prevent inherited diabesity in mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farré, Núria|||0000-0003-3110-6572
  • Santos, David|||0000-0003-1157-4969
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Metso, Jari
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Errico, Teresa Laura
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Human apolipoprotein A-I (hApoA-I) overexpression improves high-density lipoprotein (HDL) function and the metabolic complications of obesity. We used a mouse model of diabesity, the db/db mouse, to examine the effects of hApoA-I on the two main functional properties of HDL, i.e., macrophage-specific reverse cholesterol transport (m-RCT) in vivo and the antioxidant potential, as well as the phenotypic features of obesity. HApoA-I transgenic (hA-I) mice were bred with nonobese control (db/+) mice to generate hApoA-I-overexpressing db/+ offspring, which were subsequently bred to obtain hA-I-db/db mice. Overexpression of hApoA-I significantly increased weight gain and the incidence of fatty liver in db/db mice. Weight gain was mainly explained by the increased caloric intake of hA-I-db/db mice (.